LNWWM
TLSI icon

Laird Norton Wetherby Wealth Management’s TriSalus Life Sciences TLSI Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,950
Closed -$341K – 976
2024
Q1 		$341K Hold
34,950
– – 0.02% 702
2023
Q4 		$295K Buy
+34,950
New +$180K 0.02% 728

Other funds holding TLSI

DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's TLSI Position: Q2 2024 in Review

Laird Norton Wetherby Wealth Management sold out of TriSalus Life Sciences (TLSI) in Q2 2024, closing a stake of 34,950 shares — an estimated $341K sold.

Laird Norton Wetherby Wealth Management first reported a position in TLSI in Q4 2023 and held it in 2 quarters. The position peaked at $341K in Q1 2024. 28 funds tracked by Wall St. Rank hold TLSI as of Q2 2024.

  • Laird Norton Wetherby Wealth Management reported no remaining TriSalus Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Laird Norton Wetherby Wealth Management sold 34,950 TriSalus Life Sciences shares in Q2 2024, an estimated $341K.
  • Laird Norton Wetherby Wealth Management first reported a position in TriSalus Life Sciences in Q4 2023 and held it in 2 quarters.
  • Laird Norton Wetherby Wealth Management's TriSalus Life Sciences position peaked at $341K in Q1 2024.
  • 28 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2024.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q2 2024, filed 14 Aug 2024.